-
公开(公告)号：US11261170B2
公开(公告)日：2022-03-01
申请号：US16879204
申请日：2020-05-20
Inventor： Jiawang Zhu , Zhiquan Song , Dong Long , Lichun Wang , Jingyi Wang
IPC: C07D401/04 , A61P1/16 , C07D215/14 , C07D215/227 , C07D215/36 , C07D215/38 , C07D333/56 , C07D413/04
Abstract: The invention relates to an aromatic compound, pharmaceutical composition comprising the same, and a method for preparing the compound and an intermediate thereof. The invention also relates to use of the compound for the manufacture of a medicament for the prevention or treatment of a PPAR-related disease.
-
公开(公告)号：US11045455B2
公开(公告)日：2021-06-29
申请号：US16745206
申请日：2020-01-16
Inventor： Yinong Xie , Zejin You , Zhiwen Deng , Jun Zhu , Ao Wang , Yan Feng , Dong Long , Hong Zeng , Hongmei Song , Qijun Ye , Wei Qi , Donghai Su , Lichun Wang , Jingyi Wang
IPC: A61K31/437 , A61K31/519 , C07D487/04 , C07D471/04 , A61P37/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61K31/343 , A61K38/17 , A61K39/00
Abstract: The present invention relates to an azetidine derivative for use as a Janus kinase (JAK) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of JAK-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.
-
公开(公告)号：US10662214B2
公开(公告)日：2020-05-26
申请号：US15558620
申请日：2016-03-28
Inventor： Hong Ye , Gang Liu , Nan Yu , Hong Zeng , Mingliang Zhao , Yan Qing , Hua Deng , Wenjia Li , Donghong Li , Donghai Su , Wei Zhong , Shaohua Li , Xunwei Wu , Lichun Wang , Jingyi Wang
IPC: A01N43/04 , A61K31/70 , C07H19/10 , C07H19/20 , C07H1/00 , A61K31/7068 , A61K31/7076 , A61K45/06
Abstract: The present invention relates to a novel compound of 4′-thionucleoside, a preparation method therefor, a pharmaceutical composition comprising the same and an application thereof. Specifically, the present invention relates to a phosphamide derivative of 4′-thionucleoside, a preparation method therefor, a pharmaceutical composition comprising the same, a use thereof in the preparation of a medicine for preventing or treating abnormal cell proliferation diseases (for example, tumors or cancers and related diseases) or virus infectious diseases, and a method of using the same for preventing or treating abnormal cell proliferation diseases (for example, tumors or cancers and related diseases) or virus infectious diseases.
-
公开(公告)号：US20230295174A1
公开(公告)日：2023-09-21
申请号：US18017104
申请日：2021-07-23
Inventor： Zheng Gong , Hongming Li , Shidong Yi , Long Li , Tianming Wang , Pingyun Chen , Chengxi Yang , Tao Wang , Yaoyao Song , Jiangfeng Zhou , Yufeng Liang , Zhonghui Chen , Qiang Tian , Hongmei Song , Tongtong Xue , Jingyi Wang
IPC: C07D487/08
CPC classification number: C07D487/08 , C07B2200/13
Abstract: Provided are a salt and a crystal form of a pyrimidine compound, and preparation methods therefor. Specifically, provided are a salt and a crystal form of a compound I, including a crystal form of the salt, and preparation methods therefor.
-
公开(公告)号：US11207420B2
公开(公告)日：2021-12-28
申请号：US16497415
申请日：2018-04-12
Inventor： Jiaqiang Cai , Tongtong Xue , Shuai Song , Jing Wang , Qiang Tian , Liang Xiao , Hanwen Deng , Liping Liu , Zujian Tang , Hong Zeng , Rongrong Long , Hongmei Song , Qiang Zhang , Guoqing Zhong , Dengnian Liu , Haitao Huang , Ruibin Hu , Lichun Wang , Jingyi Wang
Abstract: Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3ζ molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.
-
Patent Agency Ranking
公开(公告)号：US11186599B2
公开(公告)日：2021-11-30
申请号：US17047000
申请日：2019-06-03
Inventor： Qiang Tian , Tianming Wang , Wei Liu , Baolei Zhang , Mingliang Zhao , Yufeng Liang , Jiaqiang Cai , Lichun Wang , Jingyi Wang
IPC: C07F9/6561 , C07F9/02
Abstract: The present invention relates to compounds represented by formula (I) and formula (II) and a chiral synthesis and chiral isolation method therefor, further relating to a salt and crystal form of the compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the preparation of a medicament used for the treatment of a viral infectious disease such as hepatitis B.
-
公开(公告)号：US11166954B2
公开(公告)日：2021-11-09
申请号：US16859910
申请日：2020-04-27
Inventor： Shuai Song , Jiaqiang Cai , Qiang Tian , Hong Zeng , Hongmei Song , Hanwen Deng , Zujian Tang , Xiaofan Duan , Rongrong Long , Yao Liu , Lichun Wang , Jingyi Wang
IPC: A61K31/506 , A61K31/5377 , A61P31/16
Abstract: The present invention relates to a method for prophylactically treating or treating a viral disease, comprising administering to a subject in need thereof a dihydropyrimidine compound, and the viral diseases include, but are not limited to, Hepatitis A, Hepatitis B, Hepatitis C, influenza, herpes and acquired immunodeficiency syndrome (AIDS).
-
公开(公告)号：US11136413B2
公开(公告)日：2021-10-05
申请号：US16516991
申请日：2019-07-19
Inventor： Baiyong Li , Tongtong Xue , Yu Xia , Zhongmin Maxwell Wang , Liang Xiao , Lichun Wang , Jingyi Wang
IPC: C07K16/46 , C07K14/705 , C07K16/28 , A61K39/395 , A61K47/68 , A61P35/02
Abstract: The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.
-
公开(公告)号：US11066403B2
公开(公告)日：2021-07-20
申请号：US16499610
申请日：2018-05-28
Inventor： Jianhua Ge , Zengying Han , Fengchun Chen , Shihu Jiao , Hong Zhang , Ping Zhang , Lichun Wang , Jingyi Wang
IPC: C07D471/04 , A61P19/02
Abstract: The present invention relates to a solid form of a compound of Formula (I), a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and use of the solid form in the treatment of Janus kinase (JAK) related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.
-
公开(公告)号：US10899786B2
公开(公告)日：2021-01-26
申请号：US16344317
申请日：2017-12-19
Inventor： Jiaqiang Cai , Shuai Song , Qiang Tian , Yitao Zhang , Haitao Huang , Guoqing Zhong , Wei Zhong , Yongjia Hao , Mingliang Zhao , Hong Zeng , Hongmei Song , Xin Zhou , Yao Liu , Yuting Tan , Lichun Wang , Jingyi Wang
Abstract: Provided in the present invention are a compound of Formula (I), a pharmaceutical composition comprising the same, a method for preparing the same, and use thereof as a NS5B polymerase inhibitor, a DNA polymerase inhibitor or a reverse transcriptase inhibitor for the prevention or treatment of viral diseases or cancers.
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.044 seconds)
